Category: MS Drug Therapies

High cost of MS medicines forcing patients to take ‘drastic actions’ – STAT

By ED SILVERMAN @Pharmalot  JANUARY 13, 2020 Click HERE to Register for the MS Beacon Newsletter THE high cost of multiple sclerosis…

Stuart Schlossman

Who’s Willing to Accept More DMT Risk, You or Your Neuro?

Dec 20, 2019 – By Ed Tobias As more high-efficacy disease-modifying therapies (DMTs) are being made available, people with multiple…

Stuart Schlossman

“Treating MS: A Simplified Strategy Boosts Patient and Provider Satisfaction”

Both the busy clinician and the overwhelmed patient benefit from a pointed approach to disease management. By: Aaron Boster, MD…

Stuart Schlossman

How to Find the Right MS Treatment

Diane Kramer, 35, knows all too well the challenges of finding the right multiple sclerosis (MS) treatment. When she was…

Stuart Schlossman

Biogen scores FDA nod for Tecfidera follow-up Vumerity as MS threats linger

by Eric Sagonowsky | Oct 30, 2019 Biogen on Wednesday scored FDA approval for new MS offering Vumerity. (Biogen) Biogen’s multiple sclerosis business…

Stuart Schlossman

Diagnosis and Symptoms of Secondary Progressive MS

If you have secondary progressive multiple sclerosis (#SPMS), you most likely started out with the relapsing-remitting type (#RRMS). The shift…

Stuart Schlossman

Dr Daniel Kantor Highlights MS Treatments and What Is in the Pipeline

Sept 2019 The field of treatments for multiple sclerosis (MS) has grown quickly in the last 30 years, but the…

Stuart Schlossman

a Boster Video: New MS Drug Results: #Ofatumumab vs #Teriflunomide (ASCLEPIOS trial)

Aaron Boster MD In this video I share brand new MS drug results, comparing a new B-cell killer (Ofatumamab) to…

Stuart Schlossman

Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio®* (teriflunomide) in patients…

Stuart Schlossman

EMD Serono Initiates Pivotal Phase III Program for Investigational Evobrutinib in Relapsing Multiple Sclerosis

EVOLUTION RMS 1 and 2 pivotal Phase III trials will investigate the efficacy and safety of evobrutinib in relapsing multiple…

Stuart Schlossman

Categories

Latest Blog Posts